Compounds > etofibrate
Page last updated: 2024-08-24

etofibrate and Body Weight

etofibrate has been researched along with Body Weight in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19902 (40.00)18.7374
1990's3 (60.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lang, PD; Vollmar, J1
Bocos, C; Castro, M; Herrera, E; Orozco, E; Quack, G1
Bocos, C; Castro, M; Herrera, E; Quack, G1
Benadé, AJ; Fincham, JE; Quack, G; Wülfroth, P1
Gustafson, A1

Other Studies

5 other study(ies) available for etofibrate and Body Weight

ArticleYear
[Bezafibrate and delayed action etofibrate in hyperlipidemia].
    Deutsche medizinische Wochenschrift (1946), 1983, Feb-25, Volume: 108, Issue:8

    Topics: Bezafibrate; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Triglycerides

1983
Effect of etofibrate on bile production in the normolipidemic rat.
    General pharmacology, 1995, Volume: 26, Issue:3

    Topics: Animals; Anticholesteremic Agents; Bile; Body Weight; Cholesterol; Clofibric Acid; Lipids; Male; Organ Size; Phospholipids; Rats; Rats, Sprague-Dawley; Triglycerides

1995
Studies with etofibrate in the rat. Part II: A comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysis.
    Biochimica et biophysica acta, 1993, Jul-01, Volume: 1168, Issue:3

    Topics: Adipose Tissue; Animals; Body Weight; Clofibric Acid; Hypolipidemic Agents; Lipids; Lipolysis; Liver; Male; Organ Size; Rats; Rats, Sprague-Dawley; Subcellular Fractions; Time Factors

1993
Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
    Arzneimittel-Forschung, 1996, Volume: 46, Issue:5

    Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Body Weight; Chlorocebus aethiops; Clofibric Acid; Coronary Vessels; Diet, Atherogenic; Eating; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Organ Size

1996
Treatment of hyperlipoproteinemia type II with etofibrate.
    International journal of clinical pharmacology and biopharmacy, 1979, Volume: 17, Issue:12

    Topics: Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Glucose Tolerance Test; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Liver Function Tests; Male; Middle Aged; Nicotinic Acids; Time Factors

1979